Sai Life Sciences has opened FY27 on a strong footing, reporting a 22% year-on-year jump in net profit to Rs. 73 crore for the quarter ended June 30, 2026.

 

Revenue from operations rose 12% YoY to Rs. 554 crore, compared with Rs. 496 crore in the year-ago quarter, while EBITDA increased 18% to Rs. 148 crore. EBITDA margin improved to 27% from 25%.

 

The Hyderabad-based contract research, development and manufacturing organisation (CRDMO) said growth was broad-based, with both its CRO and CDMO businesses contributing to the quarter's performance.

 

Commenting on the performance during the quarter, Krishna Kanumuri, Managing Director and CEO, Sai Life Sciences Limited, said, “We are pleased with the progress made during the quarter and the momentum we continue to see across the business. There is a clear evolution in what large pharmaceutical companies are looking for from their outsourcing partners. 

 

"The expectation is for strong, scientifically led partners who can take greater ownership of integrated discovery and development programs, rather than simply execute individual pieces of work. We believe that the combination of our technology base, scientific talent and culture is a key reason why large pharmaceutical companies are increasingly bringing significant work to Sai through strategic engagements. These engagements will create a healthy and sustained pipeline over multiple years."

 

The company's CRO business remained a key growth engine, expanding 24% year-on-year during the quarter. Meanwhile, the CMC pipeline continued to strengthen, with 33 active commercial molecules and 14 late-phase molecules, pointing to a growing base of higher-value programmes.

 

Siva Chittor, Chief Financial Officer, Sai Life Sciences Limited added, “We have begun FY27 on a healthy note, delivering revenue of Rs. 554 crore in Q1, up 12% year-on-year, with growth across both our CRO and CDMO businesses. 

 

"CRO maintained strong momentum, growing 24% year-on-year, while our CMC pipeline continues to strengthen with 33 active commercial molecules and 14 late-phase molecules. Coupled with encouraging traction in our FTE-led engagement model, a healthy balance sheet and disciplined capital allocation, we remain confident in executing our long-term growth strategy.”

 

Beyond financial performance, Sai Life Sciences expanded its research capabilities during the quarter by operationalising a new 100,000 sq. ft. R&D facility at Genome Valley in Hyderabad.

 

The company also secured an EcoVadis Platinum Rating for sustainability, placing it among the top 1% of companies assessed worldwide.